Study Group | Not treated with any lipid-lowering medication | Treated with any lipid-lowering medication | P | ||
---|---|---|---|---|---|
Total Number (n)/Percentage (%) | 1357 (83.2%) | 273 (16.8%) | |||
Male | 46.6% | 58.4 % | <0.01 | ||
Current smoker | 9.0% | 10.8% | 0.338 | ||
Consultation of a general practitioner during the last 3 months | 58.3% | 70.5% | <0.01 | ||
Arterial Hypertension (systolic BP >=140 mmHg and/or diastolic BP >=90 mmHg) | 70.5% | 83.2% | <0.01 | ||
Diabetes mellitus | 9.1% | 22.9% | <0.01 | ||
Chronic kidney disease (GFR <= 60mL/min/1,73m2) | 6.7% | 12.8% | <0.01 | ||
Coronary heart disease or equivalent | 4.2% | 24.0% | <0.01 | ||
Laboratory findings | |||||
Total cholesterol, median (IQR), mmol/L | 5.7 (5.0 – 6.3) | 4.8 (4.2 – 5.4) | <0.01 | ||
LDL-Cholesterol, median (IQR), mmol/L | 3.5 (2.9 – 4.1) | 2.6 (2.1 – 3.2) | <0.01 | ||
HDL-Cholesterol, median (IQR), all, mmol/L | 1.6 (1.3 – 1.9) | 1.5 (1.2 – 1.8) | <0.01 | ||
HDL-Cholesterol, median (IQR), by sex, mmol/L | female 1.8 (1.5–2.1) | male1.4 (1.1-1.7) | female 1.7 (1.4-2.0) | male 1.4 (1.1-1.6) | 0.04/ <0.16 |
Lipoprotein(a), median (IQR), mg/dL | 11.0 (4.2 – 31.9) | 11.0 (5.0 – 41.5) | 0.163 | ||
Triglycerides, median (IQR), mmol/L | 1.1 (0.8 – 1.5) | 1.2 (0.9 – 1.7) | <0.01 | ||
LDL-C at target, ESC-Guidelines | 5.6% | 16.5% | <0.01 |